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Cyclophosphamide (CPA) is used for the treatment of many
tumors and as a part of the conditioning regimen prior to stem cell
transplantation. CPA is a prodrug that is activated through cyto-
chrome P450 2B6 (CYP2B6) in the liver. A high degree of inter-
and intra-individual variation in CPA pharmacokinetics has been
reported. We have investigated the formation of its active metab-
olite 4-hydroxycyclophosphamide (4-OH-CPA) in vitro using
three different mutants of recombinant 2B6. The rate of formation
of 4-OH-CPA was correlated to the enzyme activity for different
mutations. Different concentrations of CPA (0-10 mM) have been
incubated with microsomes from yeast cells expressing human
CYP2B6*1 and the alleles *4, *6 as well as the point mutation
G516T. The lowest Km was observed in wild type 2B6 which also
gave the lowest Vmax (0.884 mM and 175 pmol/min/pmol P450,
respectively). The ratio of Vmax/Km was 3-4 fold higher with
CYP2B6*1 than with any of the mutants (*4, *6 and G516T).
These results did not correlate with clinical data where patients,
with hematological malignancies, having the CYP2B6 G516T mu-
tation have been shown by Xie et al to have higher rates of CPA
4-hydroxylation. In vitro, however, all three mutant alleles were
shown to have less CPA 4-hydroxylase activity than CYP2B6*1,
possibly due to the high reductase activity of the cDNA-expressed
CYP2B6*1 used as wild type for comparison.
In this paper, we propose that the discrepancy seen may depend
on the ratio between the expressed levels of NADPH-cytochrome
P450 reductase and cytochrome P450 in the cells used, especially
in those expressing CYP2B6*1. Very high reductase to P450 ratios
could enhance fast reactions, like CPA 4-hydroxylation, where the
electron transfer may be rate limiting. The ratios in the micro-
somes used are not physiologically relevant and points out one
difﬁculty in scaling from in vitro to in vivo. To evaluate the effect
of the relative amount of reductase, we also used efavirenz as a slow
substrate for CYP 2B6. Our results showed similar activity for the
mutated enzymes for efavirenz compare the clinical data in HIV-1
patients, less enzyme activity of mutants G516T and *6 involved in
efavirenz metabolism compare to wild type and also less activity
was observed for *4. We concluded that the polymorphism of the
CYP2B6 gene will inﬂuence the CPA metabolism and that it may
be important to determine the genotype of the patients before
starting treatment.
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Recently, it was demonstrated that TPO enhances hematopoietic
differentiation of primate ES cells, but its role in differentiating
human ES cells is unknown. Therefore, we sought to investigate
the regulatory mechanism of TPO induced signals mediated by the
c-mpl cytoplasmic domain during human embryonic stem (hES)
cells hematopoietic commitment. We hypothesize that in human
embryonic stem cells, binding of TPO to its c-mpl receptor causes
three-dimensional alterations which bring the c-mpl cytoplasmic
domain and Janus Kinase into close-proximity and thus induces the
phosphorylation and dimerization of STAT5 molecule. Dimerized
STAT5 molecules detach from the receptors and migrate to the
nucleus where they bind GAS site and induce transcription of a set
of target, hematopoiesis-related genes. NIH human ES cell lines
(WI01) were used. In brief, to achieve EB formation, cells were
incubated in differentiation medium, which consisted of knockout
DMEM medium (GIBCO/BRL, Carlsbad, USA), supplemented
with 20% non-heat-inactivated fetal bovine serum (FBS, Hyclone,
USA), 1% nonessential amino acids, 1 mM L-glutamine, and 0.1
mM 	-mercaptoethanol. Subsequently, DMEM was replaced by
IMDM (GIBCO/BRL, USA) with the same supplements and ad-
ditional two cytokines (100 ng/mL SCF and 100 ng/mL Flt-3
ligand (Flt-3L)) (control group). To investigate the role of TPO
and VEGF, cells were additionally treated with 100 ng/mL TPO
alone or in combination with 100 ng/mL rhVEGF. All cytokines
were from the R&D systems (USA). There was a signiﬁcant in-
crease in the numbers of embryoid bodies (EBs) formation in TPO
(125/105), TPO/VEGF (150/105 cells) when compared to controls
(10/105 planted ES cells). This corresponded to the increase in
CFU-C and speciﬁc progenitors (CD31/CD34 positive) and in
hematopoietic (CD34-positive cells) cells. Analysis of gene expres-
sion during hematopoietic development demonstrated that TPO/
VEGF combination increased mRNA expression of the TPO re-
ceptor (TPO-R) and VEGF (VEGF-R) receptors in hematopoietic
progenitors as well as CD34 cells. We are in the process of
determining the role of JAK/STAT pathway .in this process. Func-
tional studies will involve blocking of TPO/c-mpl using TPO-R-
speciﬁc antibodies and determining its impact on human ES-
derived hematopoiesis.
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Clinical conditions of the small bowel such as congenital or
surgical resection may affect the functional capability of the mu-
cosal lining of the intestinal tract. Despite recent advances in small
bowel transplantation, organ shortages remain an issue. Models
that mimic the intestinal niche provide opportunities to evaluate
stem cell development. Neointestinal engineering from intestinal
epithelial organoid units (IEOU) may be a potential alternative
therapy to solve the problems of acute organ shortage and rejection
in short bowel syndrome (SBS) patients. A novel in vitro enzymatic
digestion method to simulate the intestinal stem cell niche was
developed in a rat system. Citrulline, an amino acid exclusively
synthesized by intestinal epithelial cells, was analyzed in a primary
culture for up to 100 days. Three distinct periods of citrulline levels
were observed in the culture system. A strong correlation between
citrulline and lactate was demonstrated. Addition of rodent bone
marrow derived mesenchymal cells increased citrulline synthesis
following long term culture. This cellular niche model and the
inﬂuence of non-hematopoietic cells should have utility in tissue
engineering projects.
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Several molecular pathways that regulate hematopoietic stem cell
(HSC) self-renewal in the mouse have recently been elucidated,
including Notch, HOXB4, Wnt and bone morphogenetic protein
signaling pathways. However, full elucidation of the intrinsic and
extrinsic mechanisms that regulate human HSC self renewal has
yet to be realized. As a model for identifying extrinsic factors that
stimulate human HSC self-renewal, we have studied the capacity
for vascular endothelial cells to support human HSC expansion ex
vivo. We have found that primary human brain-derived endothelial
cells (HUBECs), unlike all other tissue sources of human ECs we
have studied, support a 1-2 log ampliﬁcation of human bone
marrow and cord blood HSCs in short term culture, in the absence
of contact (Blood 105:576-83, Blood 100:4433-39). These results
indicate that HUBECs are an ideal resource to identify novel
soluble growth factors that trigger human HSC self-renewal and
expansion. In this study, we applied a comprehensive gene expres-
sion strategy to identify the secreted gene products differentially
expressed by HUBECs as compared to ECs from a wide range of
non-brain tissues, including aorta, pulmonary artery, iliac artery,
dermal artery and coronary artery. RNA was isolated from 9
different non-brain ECs and 6 different HUBECs, each of which
has been shown by our laboratory to promote human HSC expan-
sion in vitro. Samples were hybridized to Operon Human v.3
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